Yong Eun Park

Yong Eun Park

Auto-generated profile, based on publicly available information

Yong Eun Park

Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
YPYong Eun Park
Yong Eun Park
TKTae-Oh Kim
Tae-Oh Kim
Park YE, et al. World J Mens Health. 2019 Jan;37:e14. https://doi.org/10.5534/wjmh.190007

6 December 2016 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
JPJihye Park
Jihye Park
JCJae Hee Cheon
Jae Hee Cheon
YPYong Eun Park
Yong Eun Park
YLYoon Jee Lee
Yoon Jee Lee
HLHyun Jung Lee
Hyun Jung Lee
WKWon Ho Kim
Won Ho Kim

Verified
Journal Article
Open access
PDF file
JNJi-Eun Na
Ji-Eun Na
YPYong-Eun Park
Yong-Eun Park
JPJong-Ha Park
Jong-Ha Park
TKTae-Oh Kim
Tae-Oh Kim
JLJong Yoon Lee
Jong Yoon Lee
SHSeung-Min Hong
Seung-Min Hong
Background: Few studies have compared the efficacy and safety of second-line biological therapies in ulcerative colitis (UC) patients with prior exposure to anti-tumor necrosis factor (TNF) therapy. We aim to compare the efficacy and safety between ustekinumab, vedolizumab, and tofacitinib, a current option as second-line biological therapy with different mechanisms in those patients. Methods: This retrospective multi-center study was conducted across five institutions from 2011 to 2022. We enrolled patients with moderate to severe UC who failed anti-TNF therapy and subsequently received ustekinumab, vedolizumab, or tofacitinib as second-line biological therapy. The outcomes were analyzed for clinical response/remission and endoscopic improvement/remission rates after induction therapy, drug persistency, and adverse events. Results: A total of 70 UC patients were included and grouped into ustekinumab (11 patients), vedolizumab (40 patients), and tofacitinib (19 patients) treatments. The clinical response/remission rates after induction therapy were similar between ustekinumab (90.9/81.8%), vedolizumab (92.5/65.0%), and tofacitinib (94.7/73.7%). There were no significant differences in the endoscopic improvement/remission rates between the three groups: 90.9/18.2% for ustekinumab, 72.5/12.5% for vedolizumab, and 84.2/26.3% for tofacitinib. Drug persistence was similar across the three agents (p = 0.130). Three patients of the tofacitinib group experienced adverse events (herpes zoster and hypertriglyceridemia). Conclusions: Based on real-world data, second-line biological therapy with ustekinumab, vedolizumab, and tofacitinib showed comparable efficacy in patients with moderate to severe UC with prior exposure to anti-TNF therapy.

1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JKJae Hoon Kim
Jae Hoon Kim
JNJi Eun Na
Ji Eun Na
JLJeonghwan Lee
Jeonghwan Lee
YPYong Eun Park
Yong Eun Park
JLJin Lee
Jin Lee
SPSeung Ha Park
Seung Ha Park
Kim JH, et al. J Korean Med Sci. 2023 Dec;38:e412. https://doi.org/10.3346/jkms.2023.38.e412

30 January 2020 in Intestinal Research
Verified
Journal Article
Open access
YPYong Eun Park
Yong Eun Park
YPYehyun Park
Yehyun Park
SPSoo Jung Park
Soo Jung Park
TKTae Il Kim
Tae Il Kim
WKWon Ho Kim
Won Ho Kim
JCJae Hee Cheon
Jae Hee Cheon
Patients with inflammatory bowel disease (IBD) are usually hospitalized because of aggravated gastrointestinal symptoms. Many clinicians empirically advise these patients to fast once they are admitted. However, there has been no evidence that maintaining a complete bowel rest improves the disease course. Therefore, we aimed to investigate the effects of fasting on disease course in admitted patients with IBD or intestinal Behçet's disease. A total of 222 patients with IBD or intestinal Behçet's disease, who were admitted for disease-related symptoms, were retrospectively analyzed. We divided them into 2 groups: fasting group (allowed to take sips of water but no food at the time of admission) and dietary group (received liquid, soft, or general diet). On admission, 124 patients (55.9%) started fasting and 98 patients (44.1%) started diet immediately. Among patients hospitalized through the emergency room, a significantly higher proportion underwent fasting (63.7% vs. 21.4%, P<0.001); however, 96.0% of the patients experienced dietary changes. Corticosteroid use (P<0.001; hazard ratio, 2.445; 95% confidence interval, 1.506-3.969) was significantly associated with a reduction in the disease activity score, although there was no significant difference between the fasting group and the dietary group in disease activity reduction (P=0.111) on multivariate analysis. In terms of disease activity reduction, there was no significant difference between the fasting and dietary groups in admitted patients with IBD, suggesting that imprudent fasting is not helpful in improving the disease course. Therefore, peroral diet should not be avoided unless not tolerated by the patient.

8 July 2022 in Medicine
Verified
Journal Article
Open access
SJSu Jin Jeong
Su Jin Jeong
JLJinho Lee
Jinho Lee
EKEunju Kim
Eunju Kim
JHJun Seong Hwang
Jun Seong Hwang
JLJin Lee
Jin Lee
YPYong Eun Park
Yong Eun Park
Colorectal cancer is a common cancer; generally, adults aged ≥ 50 years are screened using stool occult blood tests and colonoscopy. However, colorectal adenoma and cancer have been found in patients under the aged of 50, and studies on characteristics and risk factors in young patients are lacking. We evaluated the prevalence and risk factors of colorectal adenoma and cancer in young adults aged under 50 years. We retrospectively analyzed 570 individuals aged under 50 years who underwent colonoscopy at the Haeundae Paik Hospital, Korea, from January to June 2018. Logistic regression model was used to identify the risk factors for colorectal adenoma and colorectal cancer. The prevalence of colorectal adenoma in group of 19–29 years was 3.2% (1 of 31), 30–39 years was 13.8% (30 of 217) and in the group of 40–49 years was 21.1% (68 of 322) (P = .009). In multivariable analysis, age over 45 years (adjusted odds ratio [OR], 1.941; 95% confidence interval [CI], 1.187–3.172; P = .008) and male sex (adjusted OR, 1.711; 95% CI, 1.044–2.806; P = .033) were independent risk factors for colorectal neoplasia including cancer. The prevalence of colorectal adenoma increases as the age increased in young adults under 50 years of age, especially after the age of 45 years, the risk of colorectal neoplasia increases; hence, early screening should be considered before the age of 50 years.